Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
The Foundation announced the project in February, saying in a post on its website that has since been edited that it was time ...
Brazil's National Health Surveillance Agency (Anvisa) has approved the drug Awiqli, produced by the pharmaceutical company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback